Core Insights - Dermata Therapeutics is advancing its Phase 3 STAR-1 trial for XYNGARI™, a novel topical treatment for moderate-to-severe acne, with topline results expected by the end of March 2025 [1][2] Company Overview - Dermata Therapeutics is a late-stage biotechnology company focused on treating medical and aesthetic skin conditions, with its lead product candidate being XYNGARI™, derived from a freshwater sponge [8] - The company is headquartered in San Diego, California, and is also developing a second product candidate, DMT410, for needle-free delivery of botulinum toxin [8] Product Details - XYNGARI™ is designed as a once-weekly topical treatment that targets the root causes of acne through multiple mechanisms of action, including reducing inflammation and unclogging pores [3][5] - The Phase 3 STAR-1 trial enrolled 520 patients aged 9 years and older in the U.S. and Latin America, focusing on the efficacy, safety, and tolerability of XYNGARI™ [4] Market Context - Over 30 million acne patients seek treatment annually in the U.S., with a significant unmet need for effective acne therapies [7] - Acne affects approximately 85% of U.S. teenagers and can persist into adulthood, leading to social stigma and lowered self-esteem [7]

As filed with the Securities and Exchange Commission on February 26, 2025 Registration No. 333-284115 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NeOnc Technologies Holdings, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2834 92-1954864 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Ide ...

As filed with the Securities and Exchange Commission on January 30, 2025 Registration No. 333-284115 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NeOnc Technologies Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 92-1954864 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Iden ...

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on January 21, 2025 Registration No. 333-284064 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ASCENTAGE PHARMA GROUP INTERNATIONAL (Exact name of Registrant as specified in its charter) Cayman Islands (State or Other Jurisdiction of Incorporation or Organization) 2834 (Primary Standard Industrial Classification Code Number) Not A ...

As filed with the Securities and Exchange Commission on January 2, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NeOnc Technologies Holdings, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2834 92-1954864 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 2 Dole ...

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on December 27, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ASCENTAGE PHARMA GROUP INTERNATIONAL (Exact name of Registrant as specified in its charter) Cayman Islands (State or Other Jurisdiction of Incorporation or Organization) 2834 (Primary Standard Industrial Classification Code Number) 68 Xinqing Road Suzhou Indust ...

As filed with the U.S. Securities and Exchange Commission on September 3, 2024 Registration No. 333-260183 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 PRE-EFFECTIVE AMENDMENT NO. 19 TO Form S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 JUPITER NEUROSCIENCES, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2834 47-4828381 (Primary Standard Industrial Classification Code Number) Jupite ...

As filed with the Securities and Exchange Commission on July 17, 2024 (State or other jurisdiction of incorporation or organization) Delaware 2834 93-2403210 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) Suite 105, 8 Century Circuit Norwest, NSW 2153 Australia +61 409 840 786 (Address, including zip code, and telephone number, including area code, of registrant's principal executive offices) Registration No. 333-280670 UNITED STATES SECURITIES AND EXCHANGE ...

As filed with the Securities and Exchange Commission on July 3, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 2834 93-2403210 (I.R.S. Employer Identification Number) Suite 105, 8 Centur ...

As filed with the Securities and Exchange Commission on June 14, 2024. Registration No. 333-279121 UNITED STATES SECURITIES AND EXCHANGE COMMISSION AMENDMENT NO. 1 to FORM S-1 Washington, D.C. 20549 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SERINA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in our Charter) Delaware 2834 82-1436829 (State or Other Jurisdiction of Incorporation or Organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification ...